Endocervical atypical glandular cells of undetermined significance II.: Morphometric and cytologic analysis of nuclear features useful in characterizing differently correlated subgroups

被引:10
作者
Cenci, M
Mancini, R
Nofroni, I
Vecchione, A
机构
[1] Univ La Sapienza, Dept Expt Med & Pathol, I-00162 Rome, Italy
[2] Univ La Sapienza, Dept Med Stat, I-00162 Rome, Italy
关键词
cervix neoplasms; cervical smears; human papilloma virus; tamoxifen; cell nucleus; atypical glandular cells of undetermined significance; morphometric image analysis;
D O I
10.1159/000328473
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
OBJECTIVE: To evaluate whether some nuclear features analyzed by morphometry and cytology may be useful in characterizing differently correlated endocervical atypical glandular cells of undetermined significance (AGUS) subgroups. STUDY DESIGN: Fifty four endocervical AGUS smears were subclassified into four subgroups on the basis of their different correlation: not otherwise specified subgroup (NOSs), tamoxifen (Ts), human papillomavirus infection (HPVs) and laser therapy (LTs). Area and shape of the atypical nuclei detected were morphometrically measured. The smears were then cytologically reviewed, and the shape and grade of expression of hyperchomasia in AGUS nuclei were analyzed. RESULTS: AGUS cases due to T therapy showed the largest nuclear area (148.845 mu m(2); P < .0000) and the greatest anisonucleosis objectively measured by morphometry. HPVs had the shape that most differed from perfectly circular (15.341 versus 14.1) and showed the highest grade of expression of nuclear density. LTs and NOSs were less well characterized than the other subgroups. CONCLUSION: Analysis of nuclear features by morphometry and cytology was useful in characterizing the AGUS subgroups Ts and HPVs.
引用
收藏
页码:327 / 331
页数:5
相关论文
共 26 条
[1]  
Benoit JL, 1996, DIAGN CYTOPATHOL, V14, P349
[2]  
BIBBO M, 1997, COMPREHENSIVE CYTOPA
[3]   Endocervical atypical glandular cells of undetermined significance I.: Morphometric and cytologic characterization of cases that "cannot rule out adenocarcinoma in situ" [J].
Cenci, M ;
Mancini, R ;
Nofroni, I ;
Vecchione, A .
ACTA CYTOLOGICA, 2000, 44 (03) :319-326
[4]  
CENCI M, 1997, PATHOLOGICA, V6, P693
[5]   MUCINOUS AND CLEAR-CELL ADENOCARCINOMAS OF THE ENDOMETRIUM IN PATIENTS RECEIVING ANTIESTROGENS (TAMOXIFEN) AND GESTAGENS [J].
DALLENBACHHELLWEG, G ;
HAHN, U .
INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY, 1995, 14 (01) :7-15
[6]  
Gill BL, 1998, DIAGN CYTOPATHOL, V19, P417, DOI 10.1002/(SICI)1097-0339(199812)19:6<417::AID-DC3>3.0.CO
[7]  
2-P
[8]  
GIOVAGNOLI MR, 1995, MINERVA GINECOL, V47, P65
[9]  
Gu M, 1997, DIAGN CYTOPATHOL, V16, P96
[10]  
Kurman RJ, 1994, BETHESDA SYSTEM REPO